ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Spondyloarthropathies"

  • Abstract Number: 0554 • ACR Convergence 2024

    Different Prevalence of Intestinal Inflammation in Radiographic and Non-radiographic Axial Spondyloarthritis. Data from EISER Study

    Carolina Merino1, Zulema Plaza2, Jordi Gratacos Masmitja3, Iago Rodríguez-Lago4, Elisa Trujillo5, Ignacio Marin-Jimenez6, Eva Perez Pampin7, Manuel Barreiro8, Vanesa Hernández-Hernández9, Marta Carrillo-Palau10, Maria Luz Garcia Vivar11, Maria Carmen Muñoz12, María Lourdes Ladehesa-Pineda13, Eva Iglesias Flores14, Yago González-Lama15, Marta Arevalo Salaet16, Xabier Calvet17, Ana Gutierrez-Casbas18 and JESUS SANZ SANZ19, and EISER group, 1Hospital Universitario Puerta de Hierro Majadahonda., Majadahonda (Madrid), Spain, 2Fundacion Española de Reumatología, Madrid, Spain, 3University Hospital Parc Taulí, Sabadell, Spain, 4Gastroenterology department. Hospital Universitario Galdakao-Usansolo, Instituto de Investigación Sanitaria Biobizkaia, Galdakao, Bizkaia, Spain, Galdakao, Spain, 5Rheumatology department. Hospital Universitario de Canarias, La Laguna. Tenerife, Spain, 6Gastroenterology department. Hospital Universitario Gregorio Marañón, Madrid, Spain, 7Rheumatology department. Instituto de Investigación Sanitaria de Santiago (IDIS), Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Santiago de Compostela, Spain, 8Gastroenterology department. Hospital Clínico Universitario de Santiago de Compostela Santiago de Compostela, Spain, Santiago de Compostela, Spain, 9Hospital Universitario de Canarias, San Cristobal de La Laguna, Canarias, Spain, 10Gastroenterology department. Hospital Universitario Canarias, La Laguna, Spain., Santa Cruz de Tenerife, Spain, 11Basurto Hospital, Bilbao, Spain, 12Gastroenterology department. Hospital Universitario Basurto Hospital Universitario Basurto. Bilbao. Spain., Bilbao., Spain, 13IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Andalucia, Spain, 14Gastroenterology department. Hospital Reina Sofia, Córdoba, Spain, Cordoba, Spain, 15Servicio de Gastroenterología, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA , Madrid, Majadahonda, Spain, 16Parc Tauli Hospital Universitari I3PT, Rheumatology, Medicine Department, UAB, Sabadell, Spain, 17Gastroenterology department. Parc Taulí, Hospital Universitari. Institut d’Investigació i Innovació Parc Taulí. Universitat Autònoma de Barcelona. Sabadell, Spain, Sabadell, Spain, 18Gastroenterology department. Hospital General Universitario de Dr. Balmis de Alicante. ISABIAL y CIBERehd, Alicante, Spain, Alicante, Spain, 19Hospital Universitario Puerta de Hierro Majadahonda., Majadahonda, Spain

    Background/Purpose: Axial spondyloarthritis (AxSpA) encompasses both non-radiographic axial spondyloarthritis (nr-AxSpA) and radiographic axial spondyloarthritis (r-AxSpA), also known as ankylosing spondylitis (AS). Although nr-AxSpA is often…
  • Abstract Number: 1445 • ACR Convergence 2024

    Systematic Characterization of MRI Lesions Per ASAS Definitions in the Sacroiliac Joints of Patients with Axial Spondyloarthritis and Comparisons Among Subgroups with Psoriasis, Iritis, Colitis, AxSpA Alone, and Matched Back Pain Controls

    Ulrich Weber1, Susanne Pedersen2, Ozun Bayindir Tsechelidis3, Robert Lambert4, Joel Paschke5, Stephanie Wichuk4 and Walter Maksymowych4, 1Practice Buchsbaum Schaffhausen, Schaffhausen, Switzerland, 2Rigshospitalet, København, Denmark, 3Ottawa University, Ottawa, ON, Canada, 4University of Alberta, Edmonton, AB, Canada, 5CARE Arthritis, Edmonton, AB, Canada

    Background/Purpose: There is limited information on the frequency and topographical distribution of MRI lesions in the sacroiliac joints (SIJ) of patients with axSpA according to…
  • Abstract Number: 0564 • ACR Convergence 2024

    The Risk of Venous Thromboembolism in Axial Spondyloarthritis: A Population-based Study

    Mayas Arraf1, Devy Zisman2, walid Saliba3, Nili Stein4 and Joy Feld5, 1Technion medical school, Haifa, Israel, 2Carmel Medical Center, Haifa, Israel, 3Carmel medical center, Haifa, Israel, 4Department of Community Medicine and Epidemiology, Haifa, Israel, 5Carmel and Zvulun Medical Centre, Haifa, Israel

    Background/Purpose: Scarce data exist regarding the incidence of venous thromboembolism events (VTE); pulmonary embolism (PE) and deep vein thrombosis (DVT), in patients with axial spondylarthritis…
  • Abstract Number: 1448 • ACR Convergence 2024

    The Proportion of Inflammatory Back Pain Patients with an Abnormal Sacral MRI in a Community-Based Primary Care Setting

    Emmanuel Katsaros1, Robb Russel2, Melissa Nagare2, Cesar Ochoa1, Fanglong Dong1 and Michael Weisman3, 1Western University of Health Sciences, Pomona, CA, 2Southern California University of Health Sciences, Whittier, CA, 3Stanford University, Los Angeles, CA

    Background/Purpose: Axial spondyloarthritis (axSpA) is a group of disorders typically occurring before the age of 45 whose common features include disabling inflammatory arthritis of the…
  • Abstract Number: 0568 • ACR Convergence 2024

    Coexistence of Raynaud’s Phenomenon, Morphea or Scleroderma in Spondyloarthritis Patients: Insights from a Retrospective Cohort Study Highlighting a Unique Phenotype

    Ameesh Dev, Cary Roy, Deepak Jagannath, Alexandra Cloutet and Sarah Kazzaz, Houston Methodist Hospital, Houston, TX

    Background/Purpose: Spondyloarthritis (SpA) is a heterogeneous group of inflammatory arthritides that includes ankylosing spondylitis (AS), psoriatic arthritis (PsA), enteropathic-related arthritis, reactive arthritis, and undifferentiated SpA.…
  • Abstract Number: 1459 • ACR Convergence 2024

    Dietary Modification and Intermittent Fasting Are Common in Patients with Axial Spondylarthritis and May Lead to Reduced Inflammatory Activity

    Michael Nissen1, Adrian Ciurea2, Raphael Micheroli3, Eric Trunk4 and Delphine Courvoisier5, 1Geneva University Hospital, Geneva, Switzerland, 2University Hospital Zurich, Zürich, Switzerland, 3University Hospital Zurich, Zurich, Switzerland, 4Geneva University Hospital, Geenva, Switzerland, 5University Hospitals of Geneva, Geneva, Switzerland

    Background/Purpose: Current EULAR recommendations highlight the importance of a healthy, balanced diet in patients with inflammatory rheumatic disease, including axial spondylarthritis (axSpA). A Mediterranean-style diet…
  • Abstract Number: 0572 • ACR Convergence 2024

    Synergistic Impact of the Non-radiographic Axial Spondyloarthritis Subtype and Female Sex on First-Line Biologic Discontinuation : A Study of Interaction Effects

    Patricia Remalante-Rayco1, Emmanuel Baja2, Zeynep Baskurt3, Tina Chim4, Robert Inman5, Leonila Dans6 and Nigil Haroon7, 1Schroeder Arthritis Institute, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, 2Institute of Clinical Epidemiology, National Institutes of Health, University of the Philippines Manila, Manila, Philippines, 3Department of Biostatistics, University Health Network, Toronto, Canada, 4Schroeder Arthritis Institute, Toronto Western Hospital, University Health Network, Toronto, Canada, 5University Health Network, Toronto, ON, Canada, 6Department of Clinical Epidemiology, College of Medicine, University of the Philippines Manila, Manila, Philippines, 7Department of Medicine/Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Recent evidence suggests lower response rates to tumor necrosis factor inhibitors (TNFi) among women with non-radiographic axial spondyloarthritis (nr-axSpA). However, there is a paucity…
  • Abstract Number: 1471 • ACR Convergence 2024

    Sex-related Differences in Efficacy and Safety Outcomes in Axial Spondyloarthritis Randomized Clinical Trials: A Systematic Literature Review and Meta-analysis

    Angel Gao1, Jordi Pardo Pardo2, Steven Dang3, Lianne S Gensler4, Philip Mease5 and Lihi Eder6, 1Queens University, Kingston, Canada, 2University of Ottawa, Ottawa, Canada, 3Women's College Hospital, Institute of Medical Science, University of Toronto, Toronto, ON, Canada, 4Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, 5Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, 6University of Toronto, Women’s College Hospital and Department of Medicine, Toronto, ON, Canada

    Background/Purpose: Limited information exists on sex-related differences in axial spondyloarthritis (axSpA) randomized controlled trials (RCTs). Through a systematic literature review and meta-analysis we aimed to assess…
  • Abstract Number: 0575 • ACR Convergence 2024

    Combined Testing of anti-CD74 IgA and Anti-UH-axSpA Antibodies Increases the Diagnostic Potential for axSpA

    Kurt de Vlam1, Pieter Ruytinx2, Elien luyten2, Anouk Agten2, Frank Vandenabeele2 and Veerle somers2, 1Department of Rheumatology, UZ Leuven, and Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, KU Leuven, Leuven, Belgium, 2Universiteit Hasselt, Hasselt, Belgium

    Background/Purpose: Diagnosis of axial spondyloarthritis (axSpA) is challenging and a specific laboratory diagnostic test is lacking. Previously, we identified novel immunoglobulin G (IgG) and IgA…
  • Abstract Number: 1482 • ACR Convergence 2024

    Predictors of Clinical Response to Intravenous Secukinumab Among Patients with Axial Spondyloarthritis: A Post Hoc Analysis of a Phase 3 Trial

    Atul Deodhar1, Eva Dokoupilova2, Cynthia Vizcaya3, Reema Sutariya4, Weibin Bao4, Karen Kapur3, Susanne Rohrer3 and Alan Kivitz5, 1Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, 2Medical Plus, s.r.o., Uherske Hradiste, and Masaryk University, Faculty of Pharmacy, Department of Pharmaceutical Technology, Prague, Czech Republic, 3Novartis Pharma AG, Basel, Switzerland, 4Novartis Pharmaceuticals Corporation, East Hanover, NJ, 5Altoona Center for Clinical Research, Duncansville, PA

    Background/Purpose: This post hoc analysis of the INVIGORATE-1 study evaluated potential predictors of Ankylosing Spondylitis international Society (ASAS) 40 response in patients with axial spondyloarthritis…
  • Abstract Number: 0078 • ACR Convergence 2024

    Inhibition of the Deubiquitinase TRABID in a Pre-clinical Mouse Model of Axial Spondyloarthritis Decreases Disease Severity

    Archita Srinath1, Daniele Mauro2, Mariia Korshko3, Shaghayegh Foroozan4, Mansi Aparnathi5, Francesco Ciccia6 and Nigil Haroon7, 1University of Toronto, Toronto, ON, Canada, 2University of Campania, Italy, Naples, Naples, Italy, 3University Health Network, Toronto, ON, Canada, 4University Health Network/University of Toronto, Toronto, ON, Canada, 5University Health Network, Toronto, Canada, 6University of Campania, Naples, Italy, 7Department of Medicine/Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Axial Spondyloarthritis is characterized by both inflammation and new bone formation. Current therapeutic targets aim to control inflammation, however, over 40% of patients do…
  • Abstract Number: 0589 • ACR Convergence 2024

    Time to Clinical Response to Secukinumab Across Disease Domains Among Patients with Psoriatic Arthritis: A Pooled Post Hoc Analysis of 4 Phase 3 Trials

    Laura Coates1, Iain McInnes2, M. Elaine Husni3, Cynthia Vizcaya4, Weibin Bao5 and Philip Mease6, 1University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom, 2University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom, 3Cleveland Clinic, Cleveland, OH, 4Novartis Pharma AG, Basel, Switzerland, 5Novartis Pharmaceuticals Corporation, East Hanover, NJ, 6Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA

    Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory disease that can manifest with considerable clinical heterogeneity. Secukinumab demonstrated improvements across the updated Group for Research and…
  • Abstract Number: 1707 • ACR Convergence 2024

    TRBV9-Targeted Bispecific T Cell-Engaging Antibodies to Reset the Autoreactive T Cell Compartment in Spondyloarthritis and HLA-DQ8 Celiac Disease

    Stephanie Glavaris, Alexander Pearlman, Jin Liu, Jiaxin Ge, Yuanxuan Xia, Kyle J. Kaeo, Tolulope Awosika, Colin Gliech, Tushar Nichakawade, Nikita Marcou, Chetan Bettegowda, Drew Pardoll, Kenneth W. Kinzler, Shibin Zhou, Bert Vogelstein, Suman Paul and Maximilian F. Konig, The Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Therapies that indiscriminately deplete all T cells carry a high risk of opportunistic infection, precluding their widespread use in T cell-mediated autoimmune diseases. Targeting…
  • Abstract Number: 0082 • ACR Convergence 2024

    Comparative Immunology of Entheseal Anchorage Sites Between Spine, Hip and Knee Demonstrates up to 70-fold Greater IL-23 Induction from Axial Enthesis Bone: A New Angle on the Failure of IL-23 Blockade in Ankylosing Spondylitis

    Mark Harland1, Paula David2, Chi Wong1, Jake Weddell1, Abhay Rao3, Almas Khan3, Jake Timothy3, Peter Loughenbury3, Robert Dunsmuir3, Vishal Borse3, Campbell MacEachern3, Antonius Pieter Van der Heuvel4, Warner Chen4, Tom Macleod1 and Dennis McGonagle5, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, Leeds, UK, Leeds, United Kingdom, 2Department of Medicine B, Sheba Medical Center, Tel Hashomer, Israel, Ramat Gan, Israel, 3Leeds Teaching Hospitals NHS Trust, Leeds, UK, Leeds, United Kingdom, 4Janssen Research & Development, LLC, a Johnson & Johnson Company, Spring House, PA, USA, Spring House, PA, 5National Institute for Health Research (NIHR) Leeds Biomedical Research Centre (BRC), Leeds Teaching Hospitals, Leeds, UK, Leeds, England, United Kingdom

    Background/Purpose: Both peripheral and axial spondyloarthropathy (SpA), psoriasis and inflammatory bowel disease are strongly linked to IL-23 pathway immunogenetics and immunology. Unexpectedly, IL-23 inhibition lacked…
  • Abstract Number: 0590 • ACR Convergence 2024

    Efficacy of Secukinumab Across the Axial Spondyloarthritis Spectrum Among Patients Grouped by Age (≥40 Years vs < 40): A PostHoc Analysis of 6 Phase 3 Trials

    Sofia Ramiro1, Corine Gaillez2, Uta Kiltz3, Lianne S Gensler4, Chaitali Pisal5, Juergen Braun6 and Alexis Ogdie7, 1Leiden University Medical Center, Bunde, Netherlands, 2Novartis Pharma AG, Basel, Switzerland, 3Rheumazentrum Ruhrgebiet Herne, Ruhr-University, D-44649 Herne, Germany, 4Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, 5Novartis Healthcare Private Limited, Hyderabad, India, 6Rheuma Praxis, Ruhr-University Bochum, Berlin, Germany, 7Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Secukinumab is an IL-17 inhibitor approved to treat axial spondyloarthritis (axSpA), including radiographic (r)-axSpA and non-radiographic (nr)-axSpA. Recent ASAS-EULAR recommendations highlight the importance of…
  • 1
  • 2
  • 3
  • …
  • 11
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology